Considering this finding, we grouped patients with PBH according to their previous history of cholecystectomy and assessed the dynamics of glucose, insulin and c-peptide during MMTT
Further outcomes were thirst perception during the preceding weeks and during the evaluation visit, 24-hour urinary output, day- and nighttime voiding frequency, quality of life, serum and urine electrolytes and osmolality, and adverse effects, e.g., gastrointestinal symptoms
Always discuss this with your healthcare professional before starting any new medication
Liu dng: Mi ngy ung 1 vin vo bui sng sau khi n
Beyond glucose control, GLP-1 analogues have demonstrated significant benefits in weight management and cardiovascular risk reduction, making them increasingly valuable in treating patients with multiple metabolic disorders
Whether GLP-1 RAs may worsen symptoms of common gastrointestinal conditions (e.g., inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux) is unclear, but interaction is likely because of GLP-1s pleiotropic effect on gastrointestinal functions
